2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS

PCT No. PCT/US94/08046 Sec. 371 Date May 14, 1996 Sec. 102(e) Date May 14, 1996 PCT Filed Jul. 21, 1994 PCT Pub. No. WO95/04713 PCT Pub. Date Feb. 16, 1995Compounds and their pharmaceutically acceptable salts suitable for treating central nervous system disorders associated with the dopamine D3 receptor activity of Formula I: wherein R1 and R2 are independently chosen from hydrogen, C1-C8 alkyl, OCH3, OH, OSO2CF3, OSO2CH3, SOR5, CO2R5, CONH2, CONR5R6, COR5, CN, SO2NH2, SO2NR5R6, SO2R5, -OCO-(C1-C6 alkyl), -NCO-(C1-C6 alkyl), -CH2O-(C1-C6 alkyl), -CH2OH, -CO-Aryl, -NHSO2-Aryl, -NHSO2-(C1-C6 alkyl), phthalimide, thiophenyl, pyrrol, pyrrolinyl, oxazolyl, or R1 and R2 together form -O(CH2)1-2O- or -(CH2)3-6- (except that only one of R1 and R2 can be hydrogen or OH in any such compound); R3 and R4 are independently chosen from C2-C4 alkenyl, C3-C8 alkynyl, C3-C8 cycloalkyl, -(CH2)p- thienyl (where p is 1-4), or C1-C8 alkyl (except where R1 or R2 are hydrogen or OH or where both R1 and R2 are OCH3 or a C1-C8 alkyl); R5 is hydrogen, C1-C8 alkyl, C2-C4 alkenyl, C3-C8 cycloalkyl; and R6 is C1-C8 alkyl, C2-C4 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, or Aryl.